These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 37359088)
1. Clinical features and treatment outcomes of progressive uveal melanoma. Rancelyte M; Pamedys J; Grigiene R; Brasiuniene B Arch Clin Cases; 2023; 10(2):102-106. PubMed ID: 37359088 [TBL] [Abstract][Full Text] [Related]
2. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial. Tong TML; van der Kooij MK; Speetjens FM; van Erkel AR; van der Meer RW; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Burgmans MC; Kapiteijn E Trials; 2022 Feb; 23(1):137. PubMed ID: 35152908 [TBL] [Abstract][Full Text] [Related]
3. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone. Afzal MZ; Mabaera R; Shirai K J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557 [TBL] [Abstract][Full Text] [Related]
10. Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. Takahashi A; Namikawa K; Ogata D; Nakano E; Jinnai S; Nakama K; Tsutsui K; Muto Y; Mizuta H; Yamazaki N J Dermatol; 2020 Nov; 47(11):1267-1275. PubMed ID: 32725685 [TBL] [Abstract][Full Text] [Related]
11. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG. Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571 [TBL] [Abstract][Full Text] [Related]
12. A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma. Minor DR; Kim KB; Tong RT; Wu MC; Kashani-Sabet M; Orloff M; Eschelman DJ; Gonsalves CF; Adamo RD; Anne PR; Luke JJ; Char D; Sato T Cancer Biother Radiopharm; 2022 Feb; 37(1):11-16. PubMed ID: 35021863 [No Abstract] [Full Text] [Related]
14. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109 [TBL] [Abstract][Full Text] [Related]
15. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study. Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957 [TBL] [Abstract][Full Text] [Related]
16. The Role of Immune Checkpoint Blockade in Uveal Melanoma. Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269 [TBL] [Abstract][Full Text] [Related]
17. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665 [TBL] [Abstract][Full Text] [Related]
18. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma. Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489 [TBL] [Abstract][Full Text] [Related]
19. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511 [TBL] [Abstract][Full Text] [Related]
20. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study. Schinzari G; Rossi E; Cassano A; Dadduzio V; Quirino M; Pagliara M; Blasi MA; Barone C Melanoma Res; 2017 Dec; 27(6):591-595. PubMed ID: 29076951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]